FRESCI develops AI software and biomedical knowledge platforms, alongside scientific and regulatory strategy services, for organisations advancing human-relevant research and health technologies.
Our expertise spans New Approach Methodologies (NAMs), stem cells, advanced experimental models and translational research. We help teams organise complex evidence, assess development options and turn specialist knowledge into tools for research and industry workflows.
AI Software and Biomedical Tools
Our track record includes BimmoH, the Biomedical Models Hub developed for the European Commission’s Joint Research Centre, and NATworks, a platform mapping organisations, technologies and services across the non-animal research ecosystem.
Within VISI-ON-BRAIN, we are developing the AI architecture and evaluating models for a specialist laboratory assistant. The system is intended to integrate microscopy images, biomarker measurements and laboratory data to assess cell differentiation and provide contextual, step-by-step support to laboratory teams.
Our development pipeline also includes regulatory intelligence for vaccine testing and translational decision support for pharma, informed by our research published in the Journal of Translational Medicine.
Scientific and Regulatory Strategy
We support NAM and biomedical-platform teams preparing for partnering, funding, regulatory discussions and market adoption. Our work connects intended use, evidence quality, validation needs and stakeholder requirements, helping organisations identify gaps and define practical development roadmaps.
Scientific expertise informs our product development, while direct engagement with research and industry teams helps us build tools around specific user needs and decisions.
Collaboration Opportunities
We work with pharma and biotech companies, research institutions, testing laboratories, technology developers and public-interest organisations.
We welcome discussions with organisations seeking scientific and regulatory strategy support, industry teams interested in evaluating biomedical AI applications, and technology partners bringing expertise in multimodal AI, knowledge representation, software engineering and laboratory integration.
Our aim is to establish focused collaborations with a defined use case, clear responsibilities and measurable outcomes.
Life Science Domain
Pharma
Institutions & Public Administration
Research
Consulting Services
Medtech
Healthcare
Managing Director
FRESCI by SCIENCE&STRATEGY SL
Product
Biomedical Knowledge Platforms and AI-Assisted Databases
Commissioned biomedical databases and evidence platforms, drawing on FRESCI’s delivery experience with BimmoH and NATworks.
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain
Service
NAM and MedTech Strategy, Biomedical Business Support and Project Delivery
Specialist support for NAM adoption: from biomedical business decisions, proposal development, project management, and scientific or policy writing.
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain
Project cooperation
AI Decision Support for Cell-Therapy Workflows
Seeking research partners to develop and evaluate AI support for interpreting cell images, biomarker data and differentiation workflows.
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain
Expertise
NAM Evidence, Regulatory Science and Translational Strategy
Expertise in human-relevant models, preclinical evidence assessment, science-to-policy and the strategic requirements for adoption.
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain
Investment
MetaTool: Strategic Investment in Pharma Evidence Intelligence
Exploring investment and co-development partnerships for MetaTool, an AI-supported approach to connecting preclinical evidence with drug-development decisions.
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain
Project cooperation
MetaTool: AI for Translational Evidence Integration — EIC Pathfinder Partners
Seeking pharma partners for an EIC Pathfinder proposal to develop AI-supported integration of preclinical evidence for more transparent drug-development decisions.
Managing Director at FRESCI by SCIENCE&STRATEGY SL
Terrassa, Spain